PBYI
BEARISH
$7.24
Live
Puma Biotechnology, Inc. · NASDAQ
Target $5.0
(-30.9%)
$2.75
52W Range
$7.9
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 17, 2026
Market cap
$368.35M
P/E
11.87
ROE
28.0%
Profit margin
13.6%
Debt/Equity
0.22
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
PBYI presents a stable Piotroski F-Score of 4/9, but the stock is currently trading at a significant premium to its Graham Number ($5.96) and Intrinsic Value ($4.27). While the company maintains impressive gross margins (74.53%) and a strong ROE (27.97%), these are offset by a concerning -34.4% YoY earnings growth. With a technical trend score of 10/100 and an analyst target price of $5.00, the current price of $7.24 appears fundamentally overextended. Bearish insider activity from the CEO and CFO further suggests a lack of confidence in near-term upside.
Key Strengths
High gross profit margins of 74.53%
Strong Return on Equity (ROE) at 27.97%
Low leverage with a Debt/Equity ratio of 0.22
Healthy liquidity indicated by a Current Ratio of 2.00
Consistent history of beating quarterly earnings estimates (3/4 last quarters)
Key Risks
Current price ($7.24) is significantly higher than Intrinsic Value ($4.27)
Negative YoY earnings growth of -34.4% despite revenue growth
Strong bearish insider sentiment with sales from CEO, CFO, and Directors
Technical trend is heavily bearish (10/100)
Analyst target price ($5.00) implies a ~31% downside from current levels
AI Fair Value Estimate
Based on comprehensive analysis
$5.12
-29.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
35
40
60
65
0
AI Verdict
Overvalued with deteriorating momentum
Key drivers: Valuation gap vs Intrinsic Value, Negative earnings growth, Insider selling, Bearish technicals
Confidence
90%
Value
35/100
Ref P/E 11.87, Graham Number $5.96
Positives
- P/E ratio (11.87) is very low compared to healthcare sector average (89.84)
Watchpoints
- Price exceeds Graham Number ($5.96)
- Price exceeds Intrinsic Value ($4.27)
Future
40/100
Ref Growth rates and Target Price
Positives
- Strong YoY revenue growth of 27.70%
Watchpoints
- Significant YoY earnings contraction of -34.40%
- Bearish analyst target price
Past
60/100
Ref Historical price trends
Positives
- Exceptional 1-year price performance (+151.4%)
Watchpoints
- Poor 5-year performance (-24.3%)
- High volatility in quarterly EPS
Health
65/100
Ref Piotroski F-Score and Debt/Equity
Positives
- Low Debt/Equity (0.22)
- Strong Current Ratio (2.00)
Watchpoints
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Dividend
0/100
Ref Yield and Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.24
Analyst Target
$5.0
Upside/Downside
-30.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PBYI and closest competitors.
Updated 2026-04-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PBYI
Puma Biotechnology, Inc.
Primary
|
-24.3% | +142.1% | +151.4% | +33.8% | +17.9% | -7.2% |
|
SRZN
Surrozen, Inc.
Peer
|
-78.7% | +192.2% | +223.8% | +132.4% | +22.9% | +11.9% |
|
NAGE
Niagen Bioscience, Inc.
Peer
|
-45.0% | +228.0% | -23.6% | -37.2% | -2.3% | +4.9% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
SOPH
SOPHiA GENETICS SA
Peer
|
-68.5% | +3.5% | +86.6% | +22.5% | +7.5% | +12.3% |
PBY
Puma Biotechnology, Inc.
Primary
5Y
-24.3%
3Y
+142.1%
1Y
+151.4%
6M
+33.8%
1M
+17.9%
1W
-7.2%
SRZ
Surrozen, Inc.
Peer
5Y
-78.7%
3Y
+192.2%
1Y
+223.8%
6M
+132.4%
1M
+22.9%
1W
+11.9%
NAG
Niagen Bioscience, Inc.
Peer
5Y
-45.0%
3Y
+228.0%
1Y
-23.6%
6M
-37.2%
1M
-2.3%
1W
+4.9%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
SOP
SOPHiA GENETICS SA
Peer
5Y
-68.5%
3Y
+3.5%
1Y
+86.6%
6M
+22.5%
1M
+7.5%
1W
+12.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
11.87
Forward P/E
11.14
PEG Ratio
N/A
P/B Ratio
2.8
P/S Ratio
1.61
EV/Revenue
1.31
EV/EBITDA
6.31
Market Cap
$368.35M
Profitability
Profit margins and return metrics
Profit Margin
13.62%
Operating Margin
22.67%
Gross Margin
74.53%
ROE
27.97%
ROA
10.85%
Growth
Revenue and earnings growth rates
Revenue Growth
+27.7%
Earnings Growth
-34.4%
Q/Q Revenue Growth
+27.72%
Q/Q Earnings Growth
-30.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.22
Low debt
Current Ratio
2.0
Strong
Quick Ratio
1.86
Excellent
Cash/Share
$1.92
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
69.3%
Op. Margin
22.7%
Net Margin
17.8%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
0.66x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-26
$0.29
+26.1% surprise
2025-11-06
$0.21
+133.3% surprise
2025-08-07
$0.15
+114.3% surprise
Healthcare Sector Comparison
Comparing PBYI against 498 companies in the Healthcare sector
(28 bullish, 153 neutral, 317 bearish)
P/E Ratio
11.87
This Stock
vs
84.2
Sector Avg
-85.9%
(Discount)
Return on Equity (ROE)
27.97%
This Stock
vs
-95.47%
Sector Avg
-129.3%
(Below Avg)
Profit Margin
13.62%
This Stock
vs
-15.87%
Sector Avg
-185.8%
(Weaker)
Debt to Equity
0.22
This Stock
vs
2.89
Sector Avg
-92.4%
(Less Debt)
Revenue Growth
27.7%
This Stock
vs
137.48%
Sector Avg
-79.9%
(Slower)
Current Ratio
2.0
This Stock
vs
4.66
Sector Avg
-57.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PBYI
Puma Biotechnology, Inc.
|
BEARISH | $368.35M | 11.87 | 28.0% | 13.6% | $7.24 | |
|
SRZN
Surrozen, Inc.
|
BEARISH | $371.23M | - | -% | -% | $31.56 | Compare |
|
NAGE
Niagen Bioscience, Inc.
|
NEUTRAL | $375.58M | 23.45 | 28.3% | 13.4% | $4.69 | Compare |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
|
SOPH
SOPHiA GENETICS SA
|
BEARISH | $378.41M | - | -110.0% | -102.2% | $5.28 | Compare |
PBYI
Puma Biotechnology, Inc.
BEARISH
Mkt Cap
$368M
P/E
11.9
ROE
28.0%
Price
$7.24
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | AUERBACH ALAN H | Chief Executive Officer | Stock Award | 159,778 | - |
| 2026-02-18 | HUNT DOUGLAS M | Officer | Stock Award | 49,394 | - |
| 2026-02-18 | NOUGUES MAXIMO F. | Chief Financial Officer | Stock Award | 46,739 | - |
| 2026-01-07 | AUERBACH ALAN H | Chief Executive Officer | Sale | 34,950 | $204,878 |
| 2026-01-07 | HUNT DOUGLAS M | Officer | Sale | 8,987 | $52,696 |
| 2026-01-07 | NOUGUES MAXIMO F. | Chief Financial Officer | Sale | 10,945 | $64,187 |
| 2025-11-11 | MILLER MICHAEL PATRICK | Director | Sale | 20,000 | $97,228 |
AUERBACH ALAN H
Chief Executive Officer
2026-02-18
159,778 shares
HUNT DOUGLAS M
Officer
2026-02-18
49,394 shares
NOUGUES MAXIMO F.
Chief Financial Officer
2026-02-18
46,739 shares
AUERBACH ALAN H
Chief Executive Officer
2026-01-07
34,950 shares
·
$204,878
HUNT DOUGLAS M
Officer
2026-01-07
8,987 shares
·
$52,696
NOUGUES MAXIMO F.
Chief Financial Officer
2026-01-07
10,945 shares
·
$64,187
MILLER MICHAEL PATRICK
Director
2025-11-11
20,000 shares
·
$97,228
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
10-Q
10-Q
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Past News Coverage
Recent headlines mentioning PBYI from our newsroom.
Newest → oldest
No matching news yet.